Trial
NCT01874756
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Indiana University
Collaborators
Eli Lilly and Company
Condition
Schizophrenia
Intervention
LY500307 150mg
Why stopped
Funding ended
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-07-02